Huirong Li, Yuelin Li, Ke Li, Qianhui Wang, Jichen Yang, Ling Qiu, Jianguo Lin
{"title":"利用可激活的小分子示踪剂对肿瘤中的胰蛋白酶 B 进行正电子发射断层成像。","authors":"Huirong Li, Yuelin Li, Ke Li, Qianhui Wang, Jichen Yang, Ling Qiu, Jianguo Lin","doi":"10.1021/acs.jmedchem.4c02178","DOIUrl":null,"url":null,"abstract":"<p><p>Cathepsin B (CTB) is overexpressed in several types of tumors, and precise evaluation of the CTB activity can offer a promising method for the early diagnosis of tumors. In this study, two CTB-activated positron emission tomography (PET) tracers, <b>[</b><sup><b>68</b></sup><b>Ga]NOTA-SFCVM</b> and <b>[</b><sup><b>68</b></sup><b>Ga]NOTA-SFCVHEM</b>, were developed for sensitive and specific detection of CTB. Both tracers undergo a click condensation between 2-cyano-6-aminobenzothiazole (CBT) and cysteine (Cys) to form a cyclization product, thereby enhancing and prolonging the PET signal in tumors. <i>In vitro</i> cellular experiments showed that the tracers could differentiate tumor cells with different expression levels of CTB. <i>In vivo</i> PET imaging further revealed that the tracers selectively accumulated in the CTB-positive tumors. Compared with <b>[</b><sup><b>68</b></sup><b>Ga]NOTA-SFCVM</b>, <b>[</b><sup><b>68</b></sup><b>Ga]NOTA-SFCVHEM</b> containing a morpholine group and a histidine-glutamate-histidine-glutamate-histidine-glutamate sequence exhibited faster catalytic efficiency toward CTB, higher tumor uptake, and reduced liver uptake. These findings suggest that <b>[</b><sup><b>68</b></sup><b>Ga]NOTA-SFCVHEM</b> holds potential for clinical use in the early diagnosis of CTB-related tumors.</p>","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":" ","pages":"21292-21302"},"PeriodicalIF":6.8000,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Positron Emission Tomography Imaging of Cathepsin B in Tumors with Activable Small Molecule Tracers.\",\"authors\":\"Huirong Li, Yuelin Li, Ke Li, Qianhui Wang, Jichen Yang, Ling Qiu, Jianguo Lin\",\"doi\":\"10.1021/acs.jmedchem.4c02178\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Cathepsin B (CTB) is overexpressed in several types of tumors, and precise evaluation of the CTB activity can offer a promising method for the early diagnosis of tumors. In this study, two CTB-activated positron emission tomography (PET) tracers, <b>[</b><sup><b>68</b></sup><b>Ga]NOTA-SFCVM</b> and <b>[</b><sup><b>68</b></sup><b>Ga]NOTA-SFCVHEM</b>, were developed for sensitive and specific detection of CTB. Both tracers undergo a click condensation between 2-cyano-6-aminobenzothiazole (CBT) and cysteine (Cys) to form a cyclization product, thereby enhancing and prolonging the PET signal in tumors. <i>In vitro</i> cellular experiments showed that the tracers could differentiate tumor cells with different expression levels of CTB. <i>In vivo</i> PET imaging further revealed that the tracers selectively accumulated in the CTB-positive tumors. Compared with <b>[</b><sup><b>68</b></sup><b>Ga]NOTA-SFCVM</b>, <b>[</b><sup><b>68</b></sup><b>Ga]NOTA-SFCVHEM</b> containing a morpholine group and a histidine-glutamate-histidine-glutamate-histidine-glutamate sequence exhibited faster catalytic efficiency toward CTB, higher tumor uptake, and reduced liver uptake. These findings suggest that <b>[</b><sup><b>68</b></sup><b>Ga]NOTA-SFCVHEM</b> holds potential for clinical use in the early diagnosis of CTB-related tumors.</p>\",\"PeriodicalId\":46,\"journal\":{\"name\":\"Journal of Medicinal Chemistry\",\"volume\":\" \",\"pages\":\"21292-21302\"},\"PeriodicalIF\":6.8000,\"publicationDate\":\"2024-12-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Medicinal Chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1021/acs.jmedchem.4c02178\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/11/25 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acs.jmedchem.4c02178","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/25 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Positron Emission Tomography Imaging of Cathepsin B in Tumors with Activable Small Molecule Tracers.
Cathepsin B (CTB) is overexpressed in several types of tumors, and precise evaluation of the CTB activity can offer a promising method for the early diagnosis of tumors. In this study, two CTB-activated positron emission tomography (PET) tracers, [68Ga]NOTA-SFCVM and [68Ga]NOTA-SFCVHEM, were developed for sensitive and specific detection of CTB. Both tracers undergo a click condensation between 2-cyano-6-aminobenzothiazole (CBT) and cysteine (Cys) to form a cyclization product, thereby enhancing and prolonging the PET signal in tumors. In vitro cellular experiments showed that the tracers could differentiate tumor cells with different expression levels of CTB. In vivo PET imaging further revealed that the tracers selectively accumulated in the CTB-positive tumors. Compared with [68Ga]NOTA-SFCVM, [68Ga]NOTA-SFCVHEM containing a morpholine group and a histidine-glutamate-histidine-glutamate-histidine-glutamate sequence exhibited faster catalytic efficiency toward CTB, higher tumor uptake, and reduced liver uptake. These findings suggest that [68Ga]NOTA-SFCVHEM holds potential for clinical use in the early diagnosis of CTB-related tumors.
期刊介绍:
The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents.
The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.